Subgroup analysis of GLP-1 RA use vs. no-use in the risks of cardiovascular disease, cardiovascular mortality, and all-cause mortality showed that GLP-1 RA use was associated with a lower risk in the subgroups of gender, age, comorbidities, and drug use (Additional file 1: Table S2-S4). Here, GCG is linked to cardiovascular disorder.